Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics director-affiliated entity reports stock sales. An entity associated with director Dirk Kersten, ForDyne B.V., sold a total of 263,962 shares of Dyne Therapeutics common stock in open-market transactions on June 22–23, 2026 at weighted average prices around $20–$21 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025. Following these transactions, the entity reported holding 3,848,256 shares indirectly, and Kersten disclaims beneficial ownership except for any pecuniary interest.
Dyne Therapeutics, Inc. director Barry E. Greene received a grant of stock options covering 57,463 shares of common stock on June 22, 2026. The options have an exercise price of $20.87 per share and expire on June 21, 2036. The underlying shares are scheduled to vest in equal monthly installments over three years through June 22, 2029, indicating a multi-year equity compensation award rather than an open-market purchase or sale.
Dyne Therapeutics, Inc. director Barry E. Greene filed an initial Form 3 ownership report. This filing identifies him as a director of the company and, in the data provided, shows no reported transactions or derivative positions, with all buy, sell, and exercise counts at zero.
Dyne Therapeutics appointed Barry E. Greene to its Board of Directors as a Class I director, with a term running until the 2027 annual meeting and continuation until a successor is elected or earlier departure.
The Board determined that Greene is an independent director under Nasdaq rules. Upon joining, he received a stock option for 57,463 shares at an exercise price of $20.87 per share, vesting in equal monthly installments over three years, with full acceleration upon a change in control. He will also receive $45,000 in annual cash compensation, additional annual equity grants under the non-employee director compensation program, and reimbursement of reasonable expenses related to Board meetings.
Dyne Therapeutics, Inc. reported that an entity associated with director Dirk Kersten sold common stock under a pre-arranged trading plan. On June 17 and 18, 2026, ForDyne B.V. executed open-market sales totaling 84,355 shares at weighted average prices of about $20 per share. After these sales, ForDyne held 4,112,218 shares of Dyne Therapeutics common stock indirectly attributed to Kersten. The filing notes the transactions were made pursuant to a Rule 10b5-1 trading plan and that Kersten disclaims beneficial ownership beyond his pecuniary interest.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 887 shares of common stock at a weighted average price of $18.33 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a binding contract consistent with the Rule 10b5-1 affirmative defense. After this transaction, he holds 169,155 shares, including 145,313 unvested restricted stock units.